Gastrointestinal Tract Cancer - Pipeline Review, H2 2013

Description: Gastrointestinal Tract Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct's, 'Gastrointestinal Tract Cancer - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Gastrointestinal Tract Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Gastrointestinal Tract Cancer. Gastrointestinal Tract Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Gastrointestinal Tract Cancer.
- A review of the Gastrointestinal Tract Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Gastrointestinal Tract Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Gastrointestinal Tract Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Gastrointestinal Tract Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

- List of Tables
- List of Figures
- Introduction
- REPORT COVERAGE
- Gastrointestinal Tract Cancer Overview
- Therapeutics Development
- An Overview of Pipeline Products for Gastrointestinal Tract Cancer
- Gastrointestinal Tract Cancer Therapeutics under Development by Companies
- Gastrointestinal Tract Cancer Therapeutics under Investigation by Universities/Institutes
- Mid Clinical Stage Products
- Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Gastrointestinal Tract Cancer Therapeutics - Products under Development by Companies
Gastrointestinal Tract Cancer Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Gastrointestinal Tract Cancer Therapeutics Development
AstraZeneca PLC
Nektar Therapeutics
Millennium Pharmaceuticals, Inc.
Quest PharmaTech Inc.
BioAlliance Pharma SA
MabVax Therapeutics, Inc.
RaQualia Pharma Inc.
Gastrointestinal Tract Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
vandetanib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
etirinotecan pegol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
irinotecan hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
itriglumide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SL-052 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RQ-00000008 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
NEO-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TALL-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
SB1 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MLN-0264 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
grapiprant - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drug Targeting c-Kit - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Gastrointestinal Tract Cancer Therapeutics - Drug Profile Updates
Gastrointestinal Tract Cancer Therapeutics - Discontinued Products
Gastrointestinal Tract Cancer Therapeutics - Dormant Products
Gastrointestinal Tract Cancer - Product Development Milestones
Featured News & Press Releases
Apr 01, 2013: Indian Supreme Court Denies Patent For Novartis's Updated Version Of Leukemia Drug Glivec
Apr 01, 2013: Supreme Court Denial Of Glivec Patent Clarifies Limited Intellectual Property Protection And Discourages Future Innovation In India, Novartis Says
Jun 05, 2012: AB Science Announces Publication Of Three ASCO Presentations Detailing Results Of Masitinib In Treatment Of Advanced GIST
Feb 01, 2012: Nilki Pharma Forms Scientific Advisory Board, To Focus On Anti-cancer Compound NKP-1339
Apr 01, 2011: Neogenix Oncology To Present Data On NEO-201 At AACR's 2011 Annual Symposium
Jan 21, 2011: AVEO's Tivozanib Clinical Data To Be Presented At 2011 ASCO Gastrointestinal Cancers Symposium
Jan 12, 2011: Medimmune And Micromet Initiate Phase I Trial Of MT111 In Advanced Gastrointestinal Cancers
Nov 18, 2010: AVEO's Tivozanib In Combination With FOLFOX6 Demonstrates Anti-tumor Activity And Safety In Advanced Gastrointestinal Cancers
Oct 11, 2010: Micromet Announces FDA Acceptance Of IND For BITE Antibody MT111/MEDI-565
Nov 03, 2008: Oncolytics Biotech Inc. Collaborators Present Positive Combination REOLYSIN And Docetaxel Results at iSBTc Annual Meeting For The Trial REO 010
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products Under Development for Gastrointestinal Tract Cancer, H2 2013
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H2 2013
Number of Products under Development by Companies, H2 2013
Number of Products under Investigation by Universities/Institutes, H2 2013
Comparative Analysis by Mid Clinical Stage Development, H2 2013
Comparative Analysis by Early Clinical Stage Development, H2 2013
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
AstraZeneca PLC, H2 2013
Nektar Therapeutics, H2 2013
Millennium Pharmaceuticals, Inc., H2 2013
Quest PharmaTech Inc., H2 2013
BioAlliance Pharma SA, H2 2013
MabVax Therapeutics, Inc., H2 2013
RaQualia Pharma Inc., H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Stage and Molecule Type, H2 2013
Gastrointestinal Tract Cancer Therapeutics - Drug Profile Updates
Gastrointestinal Tract Cancer Therapeutics - Discontinued Products
Gastrointestinal Tract Cancer Therapeutics - Dormant Products
List of Figures
Number of Products under Development for Gastrointestinal Tract Cancer, H2 2013
Products under Development for Gastrointestinal Tract Cancer - Comparative Analysis, H2 2013
Products under Development by Companies, H2 2013
Products under Investigation by Universities/Institutes, H2 2013
Mid Clinical Stage Products, H2 2013
Early Clinical Stage Products, H2 2013
Discovery and Pre-Clinical Stage Products, H2 2013
Assessment by Monotherapy Products, H2 2013
Assessment by Route of Administration, H2 2013
Assessment by Stage and Route of Administration, H2 2013
Assessment by Molecule Type, H2 2013
Assessment by Stage and Molecule Type, H2 2013 29

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/2634565/](http://www.researchandmarkets.com/reports/2634565/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

<table>
<thead>
<tr>
<th>Product Name:</th>
<th>Gastrointestinal Tract Cancer - Pipeline Review, H2 2013</th>
</tr>
</thead>
<tbody>
<tr>
<td>Web Address:</td>
<td><a href="http://www.researchandmarkets.com/reports/2634565/">http://www.researchandmarkets.com/reports/2634565/</a></td>
</tr>
<tr>
<td>Office Code:</td>
<td>SCD2LPHZ</td>
</tr>
</tbody>
</table>

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
</tr>
<tr>
<td>Single User:</td>
<td>□ USD 2000</td>
</tr>
<tr>
<td>Site License:</td>
<td>□ USD 4000</td>
</tr>
<tr>
<td>Enteprise-wide:</td>
<td>□ USD 6000</td>
</tr>
</tbody>
</table>

Contact Information
Please enter all the information below in BLOCK CAPITALS

<table>
<thead>
<tr>
<th>Title:</th>
<th>Mr</th>
<th>Mrs</th>
<th>Dr</th>
<th>Miss</th>
<th>Ms</th>
<th>Prof</th>
</tr>
</thead>
<tbody>
<tr>
<td>First Name:</td>
<td>____________________________</td>
<td>Last Name:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Email Address: *</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Job Title:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Organisation:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Address:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>City:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Postal / Zip Code:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Country:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Phone Number:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fax Number:</td>
<td>____________________________</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  Please transfer funds to:

Account number  833 130 83
Sort code  98-53-30
Swift code  ULSBIE2D
IBAN number  IE78ULSB98533083313083
Bank Address  Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:  

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World